Reducing the GC dose in severe AAV patients did not significantly impact the primary outcome of death or ESRD, but did reduce the rate of infection (HR=0.69)¹

• Risk of death or ESRD with reduced GC dose was non-inferior to standard GC dose
• Reduced-dose regimen decreased the risk of serious infections (0.69; 95% CI, 0.52 to 0.93) without increasing the risk of other adverse events 
• The continued use of a standard-dose GC regimen, even in patients with severe AAV should be re-evaluated
• Use of PLEX in this patient population provided no added benefit